Dangerous Drugs and Medical Devices

Several complications and adverse events related to hernia mesh have been reported to the U.S. Food and Drug Administration (“FDA”). These complications include severe and persistent pain, infection, hernia recurrence, mesh shrinkage or migration.

IVC filters have been linked to potentially deadly complications including a high risk that pieces of metal wire will break off and puncture the vein, migrate into the heart or lungs, and cause severe injuries.

According to the U.S. Food and Drug Administration (“FDA”), metal-on-metal hip implants have unique risks not associated with other types of hip implants. For example, in metal-on-metal hip implants, friction between the ball and cup can release tiny metal particles into the space around the implant.

Xarelto has been shown to cause serious bleeding events including abdominal bleeding and brain hemorrhage. Xarelto bleeding events may lead to secondary organ damage particularly in the brain, lungs, or kidneys, and may even result in death.

One potentially devastating side effect of Taxotere is permanent alopecia (hair loss). Although many chemotherapy drugs are known to cause temporary hair loss, with most chemotherapy drugs hair begins growing back 3 – 6 months after treatment ends.

Pradaxa is known to cause severe bleeding events that may lead to disabling, life-threatening or even fatal outcomes including heart attack and stroke. Additionally, although it is intended to prevent blood clots, Pradaxa may actually cause a particularly dangerous type of blood clot in the spinal cord.

Abilify was initially approved by the U.S. Food and Drug Administration (“FDA”) in 2002. Since then studies have shown that patients who take Abilify may develop addictive behaviors including compulsive gambling, shopping, eating, and hypersexuality.

Invokana was first approved by the U.S. Food and Drug Administration (“FDA”) in March 2013. Just two years later, in May 2015, the FDA issued a drug safety communication warning patients and doctors that Invokana and other SGLT2 inhibitors may lead to a serious condition called diabetic ketoacidosis (DKA).